PL3300729T3 - Kompozycje terapeutyczne zawierające macitentan - Google Patents

Kompozycje terapeutyczne zawierające macitentan

Info

Publication number
PL3300729T3
PL3300729T3 PL17191033T PL17191033T PL3300729T3 PL 3300729 T3 PL3300729 T3 PL 3300729T3 PL 17191033 T PL17191033 T PL 17191033T PL 17191033 T PL17191033 T PL 17191033T PL 3300729 T3 PL3300729 T3 PL 3300729T3
Authority
PL
Poland
Prior art keywords
compositions containing
therapeutic compositions
containing macitentan
macitentan
therapeutic
Prior art date
Application number
PL17191033T
Other languages
English (en)
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3300729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PL3300729T3 publication Critical patent/PL3300729T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL17191033T 2008-08-13 2009-08-12 Kompozycje terapeutyczne zawierające macitentan PL3300729T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
EP17191033.4A EP3300729B1 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan
EP09786912.7A EP2315587B1 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (1)

Publication Number Publication Date
PL3300729T3 true PL3300729T3 (pl) 2020-04-30

Family

ID=41346591

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09786912T PL2315587T3 (pl) 2008-08-13 2009-08-12 Kompozycje terapeutyczne zawierające macitentan
PL17191033T PL3300729T3 (pl) 2008-08-13 2009-08-12 Kompozycje terapeutyczne zawierające macitentan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09786912T PL2315587T3 (pl) 2008-08-13 2009-08-12 Kompozycje terapeutyczne zawierające macitentan

Country Status (29)

Country Link
US (3) US8809334B2 (pl)
EP (2) EP3300729B1 (pl)
JP (3) JP5764061B2 (pl)
KR (1) KR101678699B1 (pl)
CN (1) CN102099026B (pl)
AR (1) AR073031A1 (pl)
AU (1) AU2009280843B2 (pl)
BR (1) BRPI0917661B8 (pl)
CA (1) CA2731370C (pl)
CY (2) CY1119826T1 (pl)
DK (2) DK3300729T3 (pl)
ES (2) ES2652590T3 (pl)
HK (1) HK1253355B (pl)
HR (2) HRP20171917T1 (pl)
HU (2) HUE047767T2 (pl)
IL (1) IL211143A0 (pl)
LT (2) LT3300729T (pl)
MA (1) MA32614B1 (pl)
MX (1) MX350011B (pl)
MY (1) MY178894A (pl)
NO (1) NO2315587T3 (pl)
NZ (1) NZ591601A (pl)
PL (2) PL2315587T3 (pl)
PT (2) PT3300729T (pl)
RU (1) RU2519161C2 (pl)
SI (2) SI3300729T1 (pl)
TW (1) TWI446911B (pl)
WO (1) WO2010018549A2 (pl)
ZA (1) ZA201101900B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
LT2246336T (lt) 2008-02-28 2020-08-25 Nippon Shinyaku Co., Ltd. Fibrozės inhibitorius
EP3300729B1 (en) 2008-08-13 2019-10-09 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan
WO2014110491A1 (en) 2013-01-11 2014-07-17 Theratrophix Llc Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
WO2018112258A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
KR20240119159A (ko) * 2018-09-14 2024-08-06 파모사 바이오팜 인코포레이티드 약산성 약물의 방출 제어를 위한 약제학적 조성물 및 이의 용도
PT3897646T (pt) * 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1097239A (en) 1976-05-11 1981-03-10 Salvador Moncada Enzymatic preparation of prostacyclin and its salts
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
BRPI0116237B8 (pt) * 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
KR20030059349A (ko) * 2000-12-19 2003-07-07 메르크 파텐트 게엠베하 피라졸로[４,３-ｄ]피리미딘 및 항혈전제, 칼슘 길항제,프로스타글란딘 또는 프로스타글란딘 유도체를 포함하여이루어지는 약제학적 조성물
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (pl) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
CN100379730C (zh) 2002-12-02 2008-04-09 埃科特莱茵药品有限公司 嘧啶-磺酰胺及其作为内皮素受体拮抗剂的应用
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
TWI441639B (zh) 2008-02-20 2014-06-21 Actelion Pharmaceuticals Ltd 用於治療卵巢癌之包含紫杉醇之組合
EP3300729B1 (en) 2008-08-13 2019-10-09 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan

Also Published As

Publication number Publication date
US20110136818A1 (en) 2011-06-09
MX2011001625A (es) 2011-03-29
HK1253355A1 (zh) 2019-06-14
JP2011530581A (ja) 2011-12-22
DK3300729T3 (da) 2020-01-20
EP3300729A1 (en) 2018-04-04
AU2009280843A1 (en) 2010-02-18
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
AU2009280843B2 (en) 2015-03-05
LT3300729T (lt) 2020-01-10
TWI446911B (zh) 2014-08-01
US9597331B2 (en) 2017-03-21
PT3300729T (pt) 2020-01-20
HK1253355B (zh) 2020-06-19
HUE047767T2 (hu) 2020-05-28
EP3300729B1 (en) 2019-10-09
SI2315587T1 (en) 2018-04-30
US9173881B2 (en) 2015-11-03
NZ591601A (en) 2012-12-21
DK2315587T3 (en) 2018-01-02
KR20110045006A (ko) 2011-05-03
WO2010018549A2 (en) 2010-02-18
CY1122641T1 (el) 2021-03-12
JP2015187148A (ja) 2015-10-29
JP5956026B2 (ja) 2016-07-20
ES2763176T3 (es) 2020-05-27
ZA201101900B (en) 2012-08-29
MY178894A (en) 2020-10-21
CY1119826T1 (el) 2018-06-27
CA2731370A1 (en) 2010-02-18
JP5956025B2 (ja) 2016-07-20
US8809334B2 (en) 2014-08-19
BRPI0917661A2 (pt) 2015-12-01
CN102099026B (zh) 2012-08-29
HRP20192204T1 (hr) 2020-03-06
IL211143A0 (en) 2011-04-28
HRP20171917T1 (hr) 2018-02-09
AR073031A1 (es) 2010-10-06
WO2010018549A3 (en) 2010-07-29
US20160022678A1 (en) 2016-01-28
BRPI0917661B1 (pt) 2019-12-17
SI3300729T1 (sl) 2020-02-28
ES2652590T3 (es) 2018-02-05
LT2315587T (lt) 2018-01-10
JP5764061B2 (ja) 2015-08-12
PT2315587T (pt) 2018-01-31
PL2315587T3 (pl) 2018-03-30
NO2315587T3 (pl) 2018-03-24
MX350011B (es) 2017-08-22
MA32614B1 (fr) 2011-09-01
EP2315587B1 (en) 2017-10-25
BRPI0917661B8 (pt) 2021-05-25
HUE036071T2 (hu) 2018-06-28
JP2015180683A (ja) 2015-10-15
EP2315587A2 (en) 2011-05-04
CN102099026A (zh) 2011-06-15
CA2731370C (en) 2017-03-14
RU2011109084A (ru) 2012-09-20
TW201010985A (en) 2010-03-16
US20140329824A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
HK1253355B (zh) 含有馬西替坦的治療組合物
ZA201200054B (en) Therapeutic compounds and compositions
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0814695D0 (en) Pharmaceutical compositions
IL228817A0 (en) Pharmaceutical compounds
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
PT2323623T (pt) Composições farmacêuticas
EP2236149A4 (en) MEDICAL COMPOSITION
GB0808835D0 (en) Therapeutic compositions
IL208387A0 (en) Pharmaceutical composition
GB0819958D0 (en) Therapeutic compositions
ZA201006224B (en) Pharmaceutical composition
IL206487A0 (en) Pharmaceutical compositions
GB2464200B (en) Pharmaceutical composition
GB0900786D0 (en) Therapeutic compositions
EP2490704A4 (en) THERAPEUTIC COMPOSITION
GB0817969D0 (en) Pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
GB0819960D0 (en) Therapeutic composition
GB0710144D0 (en) Therapeutic compositions
IL210519A0 (en) Anti-phthiraptera treatment compositions
GB0806283D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
EP2308842A4 (en) PHARMACEUTICAL COMPOSITIONS